Tango Therapeutics, Inc. (TNGX) AI Stock Summary

Snapshot

Tango Therapeutics is a clinical-stage biotechnology company that burns cash to fund drug development. It generated $62.4M in revenue in FY 2025, up 48% from the prior year, but lost $101.6M in net income. The losses are driven by heavy investment in research and development, which consumed $132.2M, or 212% of revenue. The company holds $343.1M in cash against $33.6M in debt, providing a runway of roughly 11 months at current burn rates. While the stock has surged from its 52-week low, it remains 28.8% below its peak. The market is pricing in the potential of its lead asset, vopimetostat, rather than current profitability.

What's Happening Right Now

• Mon 8th Jun '26 · Clinical Data: Tango reported a 92% objective response rate for its lead drug vopimetostat in combination with Revolution Medicines' daraxonrasib in pancreatic cancer patients, prompting plans for rapid Phase 3 advancement.
• Wed 13th May '26 · Earnings & Strategy: Q1 2026 results showed a $45.5M net loss and $380M in cash, with management discontinuing two older clinical programs to focus resources on vopimetostat and CNS cancer assets.
• Wed 15th Apr '26 · Leadership: The company appointed Matthew Gall as Chief Financial Officer and added other key executives to accelerate late-stage development of its lead asset.

Ownership

Institutions hold 100.0% of the shares, while insiders hold 1.8%.

Bottom Line

Tango is a high-risk, high-reward biotech play. The company is not profitable and burns through cash quickly, but it has a strong balance sheet and a lead drug showing exceptional early results in pancreatic cancer. The recent 92% response rate data is a major positive signal that could drive the stock higher if Phase 3 trials succeed. However, the tight cash runway and history of heavy spending mean the company will likely need to raise more capital soon, which could dilute shareholders. The stock is priced for success, not value.